Inositols: pharmacology and findings of clinical trials. Current evidence and prospects

Dobrokhotova, Yu.E.; Gromova, O.A.; Dukhanin, A.S.; Kumykova, Z.Kh.; Sheremetyeva, E.V.; Tabeeva, G.I.

doi:10.32364/2618-8430-2022-5-4-309-319

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Максимальную метаболическую активность имеют 2 из них -мио-инозитол и D-хироинозитол. Они образуются после эпимеризации гидроксильных групп инозитола [48]. Наиболее изученным на данный момент является мио-инозитол.…”

Section: мио-инозитолunclassified

“…Миоинозитол участвует во внутриклеточной передаче сигнала и обеспечении функционирования рецепторов инсулина, репродуктивных гормонов, факторов роста, катехоламинов и других. Он является важным синергистом фолатов, других витаминов (В5, РР) и минералов (кальций, магний), а также участвует в экспрессии переносчиков глюкозы и поглощении глюкозы клетками [48]. Есть данные о нарушении синтеза и метаболизма инозитола при диабете как 1-го, так и 2-го типов [49].…”

Section: мио-инозитолunclassified

See 1 more Smart Citation

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Dolgikh,

Bulgakova,

Sharonova

et al. 2024

ECG

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a common endocrine disease in women of reproductive age. The prevalence of this pathology is approximately 15-20%. PCOS is characterized by hyperandrogenism, hirsutism, menstrual irregularities, and polycystic ovaries. More than half of patients with PCOS have a metabolic syndrome, the main component of which is visceral obesity and insulin resistance, which play an important role in the pathophysiology of PCOS. Insulin resistance is a marker of cardiometabolic risk and can lead to cardiovascular disease and carbohydrate metabolism disorders up to type 2 diabetes mellitus (DM2). Therefore, in the treatment of patients with PCOS, an important aspect is the impact on insulin sensitivity and body weight. This review focuses on various groups of drugs that can potentially have a positive effect on metabolic disorders in PCOS. Among them are metformin, drugs with an incretin effect, as well as drugs for weight loss. Given the similarity of the metabolic and pathological features of PCOS and DM2, as well as the diversity of therapeutic options, there is a potential for expanding the strategy for the treatment of metabolic disorders in PCOS, including through antidiabetic drugs, which, however, requires further study. It should be noted that surgical treatment of obesity also has a beneficial effect and contributes to the normalization of the menstrual cycle and the normalization of the hormonal and metabolic profile in patients with PCOS and severe obesity.

show abstract

Section: мио-инозитолunclassified

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Dolgikh,

Bulgakova,

Sharonova

et al. 2024

ECG

View full text Add to dashboard Cite

show abstract

Target therapy of polycystic ovary syndrome

et al. 2023

View full text Add to dashboard Cite

Due to the complexity of the diagnosis and treatment of polycystic ovary syndrome (PCOS) in adolescents, studies are currently underway to select targeted therapy to normalize the metabolic and reproductive status of girls, including those at risk for PCOS. There are a lot of researches, that evaluate the effectiveness of inositol therapy in PCOS, ovarian dysfunction, insulin resistance (IR), ovarian hyperandrogenism in both adolescents and adult women, including those in IVF cycles. Currently, the choice of determining the ratio of myo-inositol (MI) and d-chiro-inositol (DCI) for the treatment of PCOS often leads to the physiological proportion of inositols in plasma (40:1), since research results are insufficient to unambiguously confirm it. In this connection, there is a large number of pharmaceuticals without or with a low dosage of DCI, that can’t bypass the defective epimerase activity and achieve an adequate level of DCI in the ovaries. Determination of a fair assessment and dosage of MI/DCI is required for long-term correction of metabolic, endocrinological and clinical manifestations of various PCOS phenotypes. Inositols are promising and safe treatment of hyperandrogenism, obesity, insulin resistance in women of various age groups and can also effectively complement a therapeutic effect of metformin and combined oral contraceptives.

show abstract

Systematic analysis of the pharmacology of myoinositol and D-chiroinositola

Bogacheva,

Gromova,

Torshin

2024

Fk&Fd

View full text Add to dashboard Cite

The article presents an analysis of publications on myoinositol in order to clarify the possibilities of prescribing drugs based on it. Myoinositol is one of the endogenous human metabolites that has a significant effect on the functioning of cells and tissues of the whole body. The main function of myoinositol and its derivatives is to participate in intracellular signal transmission and ensure the functioning of such important receptors as insulin receptors, catecholamines, metabotropic receptors of various neurotransmitters, growth factors, etc. (Myoinositol is the basis for the synthesis of an important group of signaling molecules, inositol phosphates, which mediate signal transmission from growth factor receptors and neurotransmitters). Most inositol-dependent proteins with known functions are necessary for the vital functions of the cardiovascular, immune system, and connective tissue structure. Equally important is the role of myoinositol in maintaining the functioning of the central nervous system (including neurotrophic and neuroprotective roles), sugar metabolism (primarily the signaling cascade of insulin) and the functioning of the kidneys and liver. Myoinositol subsidies contribute to the prevention of folate-resistant malformations and neuroprotection of the brain under stress.

show abstract

Inositols: pharmacology and findings of clinical trials. Current evidence and prospects

Cited by 3 publications

References 0 publications

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Polycystic ovary syndrome and metabolic syndrome: possible ways to correct metabolic disorders

Target therapy of polycystic ovary syndrome

Systematic analysis of the pharmacology of myoinositol and D-chiroinositola

Contact Info

Product

Resources

About